Clinical Trial Update: Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating capecitabine and lapatinib with or without cixutumumab in previously treated HER2-positive Stage IIIB-IV breast cancer; trial completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Stage Iiib Breast Cancer
• Stage Iiic Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Cixutumumab (Cixutumumab)
• Lapatinib Ditosylate (lapatinib ditosylate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2014-10-06